Discovery partnership
You bring the target. We deliver functional, validated antibody candidates in six months. Fee-for-service with milestone participation.
Fastest to start →
Written for the person who signs the deal. Deal structures, what we commit to, what we need from you, and how quickly you get an answer.
Structures are negotiable. These are the three shapes most partners start from.
You bring the target. We deliver functional, validated antibody candidates in six months. Fee-for-service with milestone participation.
Shared risk and shared upside on a program from discovery through preclinical. Antiverse retains a defined stake in the asset.
In-license an existing Antiverse program. Available for wholly-owned assets at lead-optimisation stage and beyond.
Target assessment, epitope strategy, generative library design.
De novo libraries generated and clustered by epitope and function.
Panning and functional assay against proprietary cell lines.
A diverse panel of functional, validated lead candidates.
"Six months from target to functional antibody candidates — or we talk about why."
Six partner programs. Outcome-only one-pagers published now; full versions available under NDA.
Affinity anti-PD-1 panel, diverse functional profiles. Two antibodies advancing to preclinical.
Target to functional lead candidates against a receptor previously considered intractable.
Three further programs pending publication permission. Released the day each sign-off lands.
Submit a target. Antiverse returns a written preliminary assessment within 48 hours — whether we think it's reachable, and how we'd approach it. No obligation.
Two routes, depending on where you sit. Both reach a human, not a form queue.